Ignite Creation Date:
2025-12-25 @ 4:35 AM
Ignite Modification Date:
2026-01-09 @ 5:01 AM
Study NCT ID:
NCT01015118
Status:
COMPLETED
Last Update Posted:
2017-12-07
First Post:
2009-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1199.15
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None